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Abstract
Background—It remains unclear if oral contraceptive (OC) use is associated with the incidence 
of colorectal cancer. Few studies have examined this association by duration of OC use, time since 
last OC use, and different cancer subsites.
Methods—Among 88,691 participants of the Nurses’ Health Study I (NHSI) and 93,080 
participants of the Nurses’ Health Study II (NHSII), we assessed OC use every 2 years between 
1976-2010 and categorized it as ever use, duration of use, and time since last use. We included 
incident colorectal cancer cases through 2010 (NHSI: age at diagnosis=36-88, N=1,764, NHSII: 
age at diagnosis=33-64, N=206). Multivariable hazard ratios and 95% confidence intervals [HR 
(95% CIs)] were estimated using Cox proportional hazards regression models.
Results—Ever OC use was not associated with colorectal cancer in NHSI [1.01 (0.91, 1.12)] nor 
NHSII [1.03 (0.69, 1.53)]. In NHSII, when compared to never-users, longer durations (5+ years) 
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of OC use were inversely associated with the risk of colon cancers (test for trend p=0.02) but the 
number of endpoints was limited. No other colorectal cancer subsites were associated with OC 
durations or times since last OC use in either cohort.
Conclusions—In two large prospective cohorts, we found little evidence that OC use may be 
protective for colorectal cancer, except potentially with longer durations of use among younger 
women.
Impact—Our results do not support the previous initial studies that reported an inverse 
association of recent OC use with colorectal cancer but instead support newer, larger studies 
demonstrating no such association.
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Colorectal Neoplasms/etiology; Contraceptives, Oral; Prospective Studies; Female; Age Factors
INTRODUCTION
An estimated one in 20 people in the United States will develop colorectal cancer in their 
lifetime, the third leading cause of cancer-related death with over 50,000 death expected in 
2013 (1). Women have a lower risk of developing colorectal cancer than men (41.4 
compared to 55.7 per 100,000 (2)), particularly before age 50, suggesting that sex hormones 
may play a role in colorectal carcinogenesis. A large body of literature supports that 
hormone therapy (HT) decreases colorectal cancer risk (3, 4) but the evidence for oral 
contraceptives (OC) is equivocal. Meta-analyses have estimated that OC use is associated 
with a 19% reduction in colorectal cancer (5, 6) but the two largest cohort studies were more 
recently published demonstrating no such association (7, 8).
The relationship between reproductive factors and colorectal carcinogenesis was first 
examined in the 1960s when excess colorectal cancer cases were identified in nuns 
compared to the general female population (9). This led to the hypothesis that endogenous 
hormones may play a role in colorectal carcinogenesis, as nuns generally differ in their 
hormonal exposure due to nulliparity. Soon after, researchers hypothesized that exogenous 
hormones may decrease colorectal cancer risk as well, including a proposed mechanism of 
estrogen reducing secondary bile acid production (10, 11). This was followed by further 
evidence from observational studies, including cohort (12-20) and case-control (21-31) 
studies, and randomized control trials (32), which suggested that exogenous hormone use, 
including OCs and HT, was inversely associated with colorectal cancer.
But this protective association was not observed in all studies of OC use (33-38), including 
the two largest studies (7, 8), and many were not able to examine important aspects of this 
relation. For example, some studies have not been able to explore precise exposure data such 
as duration (12, 13, 19, 22, 24-26, 30, 31) and recency of use (12, 13, 15-22, 24-26, 29-31, 
33, 34, 36-38). The most recent meta-analysis (5) highlighted that the apparent protection 
conferred by OC use may be greater for recent use, so examining aspects of the exposure, 
including timing, may be especially relevant. Other studies have not been able to examine 
potential heterogeneity of the outcome with regard to different cancer subsites (e.g., colon or 
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rectal); nor have they explored subsites within the colon (e.g., proximal or distal). 
Furthermore, most of the previous work has focused primarily on younger women, where 
the spectrum of cancers may be different than in older women. Elucidating these issues 
requires large prospective cohort data from the time that OCs debuted including precise, 
detailed exposure and outcome information.
We therefore examined the association of OC use and colorectal cancer using 
comprehensive data from two large prospective cohort studies, the Nurses’ Health Study I 
(NHSI) and II (NHSII). Two previous analyses from NHSI exist (17, 39); the most recent 
was published in 1997 and examined incident cases of colorectal cancer (N=501) that 
occurred between 1980 and 1992. Both previous analyses reported null associations except 
the 1997 analysis also found that women who had used OCs for 8+ years had a lower risk of 
developing colorectal cancer (17). With 18 additional years of follow-up (1980-2010) and 
four times as many cases (N=1,970 in NHSI and II combined), we are now able to examine 
the association between OC use and colorectal cancers in detail with excellent statistical 
power; these data allow us to examine duration and recency of use, as well as different 
cancer subsites. The NHSI women are now older and we can also analyze a new cohort of 
younger women from NHSII who used more recent OC formulations and for whom this 
association has never been examined. We hypothesized that longer durations of OC use is 
inversely associated with colorectal cancer.
MATERIALS AND METHODS
Study Population
The Nurses’ Health Study I and II are prospective cohort studies. The NHSI was established 
in 1976 among 121,701 US female registered nurses, aged 30 to 55 years, and the NHSII 
was established in 1989 among 116,609 female registered nurses, aged 25 to 42 years. 
Information about lifestyle and medical history is collected from participants in both cohorts 
via mailed biennial questionnaires. Participants complete validated, semiquantitative food 
frequency questionnaires (FFQs) approximately every four years. The follow-up in both 
cohorts has remained over 90% to date.
Due to the importance of several dietary risk factors for colorectal cancer risk, we started 
follow-up for this analysis in 1980 in NHSI and 1991 in NHSII, after the baseline dietary 
questionnaire, and therefore 72 cases were excluded due to being diagnosed before 1980 in 
NHSI though no cases met this exclusion criteria in NHSII. We also excluded women with a 
history of cancer [except for nonmelanoma skin cancer (NHSI: N=4,623 and NHSII: 
N=1,522)] and ulcerative colitis (NHSI: N=117 and NHSII: N=1,078) prior to baseline as 
well as those who did not complete the baseline dietary questionnaire—1980 in NHSI 
(N=27,327) and 1991 in NHSII (N=21,181). The final group comprised 181,771 women: 
88,691 women followed from 1980 to 2010 in NHSI and 93,080 women followed from 
1991 to 2009 in NHSII. The study was approved by the Institutional Review Board of 
Brigham and Women’s Hospital in Boston; informed consent was implied by the return of 
the baseline questionnaire.
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Assessment of Exposure
On the baseline questionnaires for both cohorts, participants were asked whether they had 
ever used OCs and, if so, to list all starting and stopping dates in order to capture all time 
periods of use. Subsequent biennial questionnaires asked whether OCs had been used during 
the previous two years and the number of months of use. We classified women as never-
users or ever-users, and defined ever use as a minimum of two months. Information was also 
collected on starting/stopping dates so we could calculate total duration of use (≤1, >1 to <2, 
≥2 to <5, ≥5 to <10, 10+ years in NHSI and ≤1, >1-<5, 5+ years in NHSII due to the number 
of cases in each stratum), time since last use (≤4, >4 to <10, ≥10 to <15, 15+ years), and a 
cross product of duration-by-time since last use (e.g., ≤1 year duration and ≤4 years since 
last use, see Table 5). We estimated duration of use by summing OC use across 
questionnaire cycles. Dynamic exposures were included as time-varying variables in all 
regression models. No information was collected on OC formulation or brand in NHSI, 
though given the timeframe, these would have been exclusively first- and second-generation 
pills (defined by progestin type). In NHSII, participants also reported detailed information 
about the OC brand and formulation but this information was not used in the current 
analyses due to the small number of NHSII colorectal cancer cases.
The reproducibility and validity of the OC data were evaluated in a study among 215 
randomly selected participants from NHSII (40). The data from biennial questionnaires were 
contrasted with data from a subsequent telephone interview that used a structured life events 
calendar. Agreement for ever use versus never use was 99%, and the correlation for duration 
of use calculated from the two sources was 0.94.
Case Ascertainment
Biennial follow-up questionnaires were used to identify newly diagnosed cases of colorectal 
cancer. We sought permission to obtain medical records and pathology reports for those who 
reported a colorectal cancer diagnosis. Cohort member deaths were identified through 
family members, the postal system, as well as the National Death Index, and we estimate 
that >98% of deaths were ascertained. For non-respondents who after review of death 
certificate were determined to have died of colorectal cancer, we requested permission from 
next-of-kin to review medical records. Information on histopathology, anatomic location, 
and stage of cancer was extracted by study physicians who were blinded to exposure 
information. We included all incident cases of adenocarcinoma colorectal, defined according 
to the International Classification of Diseases, Ninth Revision, from 1980 to 2010 in NHSI 
and from 1991 to 2009 in NHSII. The ascertainment of colorectal cancer cases has been 
described in further detail elsewhere (41). Cancers were also classified by subsite (e.g., 
proximal, distal, or rectum).
Assessment of Covariate Information
Covariates were chosen based on a priori knowledge of risk factors, including those from a 
previously developed comprehensive model of colon cancer (42). Our final model adjusted 
for age, body mass index (BMI), height, physical activity, smoking, processed and red meat, 
folate, calcium, total energy, aspirin use, alcohol intake, age at first birth, parity, HT use, 
family history, and previous endoscopy screening.
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Participant’s height (inches) was reported at baseline (NHSI: 1976, NHSII: 1989) and 
modeled as a continuous variable. Self-reported current weight (pounds) was collected on 
every questionnaire, and has high validity in these cohorts. From height and weight, we 
calculated BMI [<18.8, 18.5-22.9, 23-24.9 25-29.9, 30+ kilograms/meter2 (kg/m2)]. 
Detailed questions about physical activity were used to derive a continuous value of total 
metabolic (MET) hours/week. Information about smoking was modeled as a continuous 
variable of total pack-years. Intake of folate [microgram (mcg)/day], calcium (mcg/day), 
processed and red meat (servings/day), and total energy [kilocalories (kcal)/day] were 
accessed using the FFQs and each modeled as continuous variables from the quintile 
medians. Alcohol intake [<5, 5-9.9, 10-14.9, 15+ gram (g)/d], aspirin use (<4, 4-6, 7-10, 11+ 
times/week), age at first birth (<24, 24-25, 26-29, 30+ years), and parity (0, 1, 2, 3+ 
children) were modeled categorically. Use of HT was asked on every questionnaire 
beginning at baseline; HT use was modeled as never, premenopausal, past, or current. 
Family history of colon or rectal cancer in immediate family members was updated about 
every four years while information on endoscopy screening was provided biennielly. When 
a woman reported having an endoscopy, through sigmoidoscopy or colonoscopy, we 
assigned her two cycles (4 years) of screening “coverage” starting from the time at which 
she reported being screened (to approximately account for appropriate screening intervals). 
We then summed the total number of years of screening coverage for each woman. 
Participants could report endoscopies on every biennial questionnaire. For all regression 
analyses, dynamic exposure covariates were included as time-varying variables.
Statistical analyses
Person-time was calculated from the date of the return of the baseline questionnaire to the 
date of death, colorectal cancer diagnosis, loss to follow-up, or end of follow-up (June 
2010), whichever occurred first. Cox proportional hazards regression models were used to 
calculate hazard ratios and 95% confidence intervals [HR (95% CIs)] using age (months) 
and the year of questionnaire return as the time metameter. Analyses of colorectal cancer 
subsites were conducted using the competing risk analysis described by McNeil and Lunn 
(43). All analyses were done separately in each cohort and not combined due to different OC 
formulations (primarily first- and second generation in NHSI and second-, third-, and fourth-
generation in NHSII) and usage patterns (about half of NHSI participants used OCs 
compared to nearly 90% of NHSII participants).
We conducted interaction analyses to assess whether associations varied across categories of 
BMI (<25, 25+ kg/m2), smoking status (never, ever), alcohol consumption (<5, 5+ g/d), 
physical activity [<10.2, 10.2+ (median) MET hours/week], folate [<414, 414+ (median) 
mcg/day], family history (yes, no), or age at diagnosis (continuous years). All analyses were 
conducted with SAS software version 9.2. Trend tests were performed by modeling the 
median values of exposure categories as a continuous variable and using the Wald statistic 
to test for statistical significance. All statistical analyses were two-sided, using a 5% 
significance level.
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RESULTS
In our population of 88,691 women from NHSI with information on OC use, 45,237 were 
never-users (51%) and 43,454 were ever-users (49%) at last OC report. NHSI ever-users 
reported a 4.2-year mean duration of use. Among 93,080 NHSII participants, 12,957 were 
never-users (14%) and 80,123 were ever-users (86%) at last OC report. NHSII ever-users 
reported a 6.0-year mean duration of use. Compared to never-users in both cohorts, ever-
users were more likely to have smoked, be younger, including at first birth, have more 
children, and have used HT (Table 1).
After 30 years and 2.5 million person-years of follow-up in NHSI, we observed 1,764 
colorectal cancer cases: 1,385 colon (including 823 proximal and 521 distal) and 379 rectal 
cancers. The median age at diagnosis in NHSI was 70 and ranged from 36-88 years. After 
19 years and 2.8 million person-years of follow-up in NHSII, we observed 206 colorectal 
cancer cases: 139 colon (including 68 proximal and 69 distal) and 67 rectal cancers. The 
median age at diagnosis in NHSII was 51 and ranged from 33-64 years.
Ever using OCs in NHSI was not associated with risk of colorectal [1.01 (0.91, 1.12)], colon 
[1.04 (0.93, 1.18)], proximal [1.14 (0.98, 1.32)], distal [0.91 (0.75, 1.11)], or rectal cancer 
[0.89 (0.71, 1.12)]. OC use in NHSII was not associated with colorectal cancer [1.03 (0.69, 
1.53)] or any subsite: colon [0.91 (0.57, 1.46)], proximal 0.63 (0.35, 1.15)], distal [1.44 
(0.66, 3.16)], or rectal [1.35 (0.64, 2.85)] (Table 2).
Compared to never use, longer durations of OC use (5+ years) appeared to be associated 
with lower risk of colon cancers in NHSII (test for trend p=0.02), but not with rectal cancers 
(Table 3). Time since last OC use was not associated with risk of colorectal cancers in either 
cohort regardless of subsite (Table 4), nor was the cross product of duration-by-time since 
last use (Table 5). None of these associations varied by age at diagnosis, BMI, smoking 
status, alcohol consumption, physical activity, folate, or family history (all p values for 
interaction terms with OC use >0.05).
DISCUSSION
In NHSI and II, ever OC use was not associated with colorectal cancer. In NHSII alone, 
longer durations of OC use (5+ years) were associated with lower risk of proximal cancers 
but not distal or rectal cancers but statistical power was limited. Observed associations did 
not appear to differ by time since last OC use. The association between OC use and 
colorectal cancer in NHSI was initially examined after 8 years of follow when participants 
were 38-63 years of age (39) and then again after 12 years of follow-up when participants 
were 46-71 years of age (17). In the previous analyses, OC use was not associated with 
colorectal cancer except after 12 years of follow-up when OC use was inversely associated 
with colorectal cancer after 8+ years of use [RR=0.60 (0.40-0.89), ptrend=0.02]. Likewise, 
the present analysis found a nearly identical inverse association [(HR=0.61 (0.38, 0.99), 
ptrend=0.02] among colon cancers in a similar age group, the NHSII participants (46-63 
years of age).
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Collectively, the previous literature has spanned from the early 1980s through the 2000s 
including various OC types and age ranges. The mix of OC formulations and brands 
includes primarily first- and second-generation progestins with a range of estrogen doses but 
none of these studies have examined this information specifically. More time will need to 
pass before sufficient data are available from women using third- and fourth-generation pills 
with lower estrogen doses. Additionally, few of the other studies have examined differences 
across age or even reported the median ages at diagnosis. It appears the majority of previous 
evidence weighs heavily on younger women, where the spectrum of cancers may be 
etiologically different than in older women. The NHSI has some of the longest follow-up 
time and therefore includes more cases, including among older women, than other studies.
Previous studies have produced mixed results. Two meta-analyses (5, 6) consisting of 
primarily case-control and small cohort studies with limited statistical power, reported a 
19% reduction in colorectal cancer risk with ever OC use. The most recent meta-analysis(5) 
included 11 case-control studies, with the largest study containing 1,488 cases, and seven 
cohort studies. However, this inverse association has not been observed in all studies (7, 8, 
38, 44). For example, the authors of a case-control study including 675 cases and 720 
controls reported a reduced risk for other reproductive factors such as parity but found no 
association with OC use (44). In a similar case-control study, neither contraceptive estrogen 
use nor non-contraceptive estrogen use was related to the risk of colon cancer (38). 
Additionally, the two largest cohort studies including the National Institutes of Health-
American Association of Retired Persons Diet and Health Study with 2,014 cases and the 
European Prospective Investigation into Cancer and Nutrition with 1,878 cases were 
published after these meta-analyses with null findings (7, 8).
Previous results appear similar for colon as well as rectal cancer but, to the best of our 
knowledge, no study has examined associations by subsites within the colon (i.e., proximal 
versus distal) primarily because of limited sample size. Combining data from ten case-
control studies and five cohort studies in a meta-analysis, the relative risk for colon cancer 
was 0.85 (95% CI: 0.79-0.93) and 0.80 (95% CI: 0.70-0.92) for rectal cancer (5). Other 
reproductive factors, such as parity(18), have had heterogeneity in their association with 
colorectal cancer by subsites.
Previous studies have also examined duration and recency of OC use. The latest meta-
analysis found no difference according to duration of OC use for either colon or rectal 
cancer, although there was suggestion that the protection was stronger for more recent use 
(5). Based on duration information from twelve studies, the pooled relative risk was 0.88 
(95% CI: 0.77-1.01) for short-term use (defined as <5 years), and 0.86 (95% CI: 0.74-1.00) 
for long-term use (defined as ≥5 years). Only four studies contributed information on 
recency of OC use, resulting in an overall relative risk of 0.70 (95% CI: 0.53-0.90) for <10 
years of use and 0.87 (95% CI: 0.77-0.99) for ≥10 years of use (5). These findings are 
consistent with those from epidemiologic studies examining HT use and colorectal cancer, 
which have reported stronger effects with current use and no evidence of a dose–response 
relation with duration (3).
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Numerous mechanisms have been hypothesized for how OC use might impact colorectal 
cancer (45). Slattery et al. suggested that estrogen and high BMI interact by modulating the 
insulin-like growth factor pathway (46). Estrogen may also have direct anticarcinogenic 
effects, as demonstrated in colon cancer cell lines (47) and estrogen receptor expression in 
colonic cells (48), which may regulate numerous cellular functions related to colon 
carcinogenesis (49, 50). Issa et al proposed that estrogen may protect the estrogen receptor 
gene from methylation (51). Additionally, McMichael and Potter used epidemiological and 
animal data to suggest that endogenous and exogenous hormones could affect colorectal 
cancer risk by reducing secondary bile acid production (10). Although understanding of the 
genetic model of colorectal carcinogenesis has evolved, further investigation is needed to 
clarify such mechanisms and point toward possible interventions.
We were limited in exploring different types of OC use. For example, we lacked detailed 
formulation information in NHSI and could not use the information collected in NHSII 
because there were too few colorectal cancer cases to stratify by OC type. We also had 
limited statistical power among younger women. The generalizability of our findings may be 
limited by the homogeneity of our population with regard to race, education, and profession. 
However, these cohorts offer numerous advantages, including high follow-up rates, reliable 
information, and medically knowledgeable and cooperative participants. Our results pertain 
not only to the effects of the first- and second-generation OCs in NHSI, which had estrogen 
doses between 50-150 mcg, but also to current OC generations used in NHSII, which 
contain lower estrogen doses (20-35 mcg). Compared to other cohort studies in which this 
association has been considered, our analysis drew from two of the largest cohorts with the 
longest follow-up time. Due to the longitudinal nature of NHSI and II, we were also able to 
control for potential confounders and other hormonal exposures such as HT use that may be 
associated with colorectal cancer. Previous studies have not always been able to examine 
OC and HT use simultaneously.
In conclusion, we found little evidence that OC use may be protective for colorectal cancer, 
except potentially with longer durations of use among younger women. Our results do not 
support the previous studies that have observed stronger inverse associations with more 
recent use than with use in the more distant past. Further research should focus on 
examining different types of OCs, older ages at diagnosis, and all of the subsites of 
colorectal cancer, specifically subsites within the colon and molecular subtypes. Overall, a 
better understanding of the association between hormone use, including OCs, with the risk 
of colorectal cancer could impact how such drugs are used in clinical settings and potentially 
highlight new methods of prevention.
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Table 1
Age-standardized characteristics of ever and never OC users among 88,691 NHSI participants at the midpoint 
of follow-up (1994) between 1980-2010 and 93,080 NHSII participants at the midpoint of follow-up (2001) 
between 1991-2010 [means (SD) or %].
NHSI NHSII
Never users
(N=45,237)
Ever users
(N=43,454)
Never users
(N=12,957)
Ever users
(N=80,123)
Age, years 63.4 (6.5) 57.5 (6.4) 47.1 (4.5) 46.8 (4.7)
Height, inches 64.4 (2.4) 64.6 (2.4) 64.8 (2.7) 64.9 (2.6)
Physical activity, MET-hours/week 18.5 (22.5) 18.6 (22.7) 18.5 (23.0) 18.9 (23.7)
Smoking, pack-years 12.8 (19.7) 12.6 (18.6) 3.3 (8.0) 5.1 (9.6)
Processed or red meat, servings/day 0.4 (0.3) 0.4 (0.3) 0.7 (0.5) 0.7 (0.5)
Folate, mcg/day 443 (210) 443 (214) 612 (254) 606 (255)
Calcium, mcg/day 1,038 (473) 1,054 (483) 1,222 (510) 1,223 (529)
BMIa, kg/m2
 <18.5 5 5 17 15
 18.5-22.9 18 21 24 25
 23-24.9 17 18 13 15
 25-29.9 31 30 22 24
 30+ 20 19 23 21
Aspirin use, times/weeka
 0-3 69 70 96 95
 4-6 15 15 4b 5b
 7-10 8 8
 11+ 8 8
Alcohol, gm/daya
 <5 61 58 64 60
 5-9.9 8 9 7 9
 10-14.9 6 7 4 6
 15+ 6 8 3 5
Age at first birth, yearsa,c
 <24 34 39 27 29
 24-25 29 28 20 20
 26-29 27 24 33 34
 30+ 11 9 19 17
Paritya
 0 7 4 37 30
 1 7 6 15 19
 2 25 30 28 34
 3+ 59 58 20 17
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NHSI NHSII
Never users
(N=45,237)
Ever users
(N=43,454)
Never users
(N=12,957)
Ever users
(N=80,123)
HT usea
 Premenopausal 20 22 17 14
 Never 31 21 53 45
 Past 19 15 15 20
 Current 31 41 15 21
Endoscopy screening,
last two years
21 20 10 10
a
May not add to 100% due to missing data.
b
Highest categories were combined in NHSII due to sparse data.
c
Distribution among parous women.
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Table 2
Colorectal cancer subsites in ever and never OC users among 88,691 NHSI and 93,080 NHSII participants.
Cases HR (95% CI)
Age-adjusted Multivariablea
Never
Users
Ever
Users
Never
Users
Ever
Users
Ever
Users
NHSI
Colorectal 1,079 685 ref. 0.97 (0.87, 1.08) 1.01 (0.91, 1.12)
 Colon 844 541 ref. 1.01 (0.89, 1.13) 1.04 (0.93, 1.18)
  Proximal colon 493 330 ref. 1.10 (0.94, 1.27) 1.14 (0.98, 1.32)
  Distal colon 326 195 ref. 0.88 (0.72, 1.07) 0.91 (0.75, 1.11)
 Rectum 235 144 ref. 0.85 (0.68, 1.06) 0.89 (0.71, 1.12)
NHSII
Colorectal 29 177 ref. 0.98 (0.66, 1.46) 1.03 (0.69, 1.53)
 Colon 21 118 ref. 0.88 (0.55, 1.39) 0.91 (0.57, 1.46)
  Proximal colon 14 54 ref. 0.60 (0.33, 1.09) 0.63 (0.35, 1.15)
  Distal colon 7 62 ref. 1.37 (0.62, 2.99) 1.44 (0.66, 3.16)
 Rectum 8 59 ref. 1.27 (0.61, 2.66) 1.35 (0.64, 2.85)
aAdjusted for age, BMI, height, physical activity, smoking, processed and red meat, folate, calcium, total energy, aspirin use, alcohol, age at first 
birth, parity, HT use, family history, and previous endoscopy screening.
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